Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation

Supplementary Data 6 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation

<p>Supplementary Data 6: Association between individual metabolites and radiation survival</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Priyanka Gopal (15050862) (author)
Kolejni autorzy:	Brian D. Yard (15050865) (author), Aaron Petty (15050868) (author), Jessica C. Lal (15050871) (author), Titas K. Bera (15050874) (author), Trung Q. Hoang (15050877) (author), Alexandru D. Buhimschi (15050880) (author), Mohamed E. Abazeed (14936313) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Genetic biomarkers Computational Methods Algorithms Gene Technologies Mutation detection methods Lung Cancer
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Supplementary Data 1 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
od: Priyanka Gopal (15050862)
Wydane: (2025)

Supplementary Data 2 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
od: Priyanka Gopal (15050862)
Wydane: (2025)

Supplementary Data 3 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
od: Priyanka Gopal (15050862)
Wydane: (2025)

Supplementary Data 4 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
od: Priyanka Gopal (15050862)
Wydane: (2025)

Supplementary Data 5 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
od: Priyanka Gopal (15050862)
Wydane: (2025)

Supplementary Figure S6 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Table S7 from Gene Fusion Detection and Characterization in Long-Read Cancer Transcriptome Sequencing Data with FusionSeeker
od: Yu Chen (14962271)
Wydane: (2025)

Supplementary Figure S1 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S10 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S11 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S12 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S2 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S4 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S5 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S7 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S8 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Figure S9 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
od: Leon J. Wils (15055780)
Wydane: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
od: Aleksandar Obradovic (7549517)
Wydane: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
od: Aleksandar Obradovic (7549517)
Wydane: (2025)

Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
od: Joel R. Eisner (15132120)
Wydane: (2025)

Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
od: Joel R. Eisner (15132120)
Wydane: (2025)

Supplementary Table S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
od: Joel R. Eisner (15132120)
Wydane: (2025)

Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
od: Subhamoy Chakraborty (16648124)
Wydane: (2025)

Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
od: Subhamoy Chakraborty (16648124)
Wydane: (2025)

Figure S3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
od: Subhamoy Chakraborty (16648124)
Wydane: (2025)

Supplementary Tables 1-3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
od: Subhamoy Chakraborty (16648124)
Wydane: (2025)

Figure 6 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
od: Tobias Kessler (17079209)
Wydane: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
od: Lavanya Sivapalan (15314248)
Wydane: (2025)

Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer
od: Sunho Park (15053897)
Wydane: (2025)

Figure 1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Figure 2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Figure 3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Figure 4 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Figure 5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Supplementary Table S1-S3 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
od: David Milewski (15050643)
Wydane: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
od: Tobias Kessler (17079209)
Wydane: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
od: Tobias Kessler (17079209)
Wydane: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
od: Tobias Kessler (17079209)
Wydane: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
od: Tobias Kessler (17079209)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n4au7hbgrmjq0b19ru5ekg5a8f